Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950734 | 1.00 | RAB9A (0.46) | RAB9ASLC6A2SLC6A4LMNATP53 | |
| SCHEMBL950732 | 1.00 | RAB9A (0.46) | RAB9ASLC6A2SLC6A4LMNATP53 | |
| SCHEMBL3317620 | 0.74 | ADRB2 (0.41) | RAB9ASLC6A2SLC6A4KCNH2SLC6A3 | |
| Hydrochloric Acid SCHEMBL28591270 | 0.72 | CASR (0.35) | KCNH2MC4R | |
| SCHEMBL3317547 | 0.70 | HTR6 (0.45) | SLC6A2SLC6A4LMNACYP2D6SLC6A3 | |
| SCHEMBL8210156 | 0.69 | LMNA (0.67) | RAB9ASLC6A4LMNATP53HTT | |
| SCHEMBL12330899 | 0.69 | SSTR4 (0.51) | CYP2D6 | |
| SCHEMBL31053298 | 0.69 | SSTR4 (0.51) | CYP2D6 | |
| SCHEMBL21933590 | 0.69 | SSTR4 (0.51) | CYP2D6 | |
| SCHEMBL12330949 | 0.69 | SSTR4 (0.51) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | RAB9A 1009/4885SLC6A2 1059/4885SLC6A4 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.